Navigation Links
Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques
Date:10/13/2008

Oshkosh is one of six sites included in national study

Study needed because of low cardiac arrest survival rates

OSHKOSH, Wis., Oct. 13 /PRNewswire/ -- Advanced Circulatory Systems, Inc. (http://www.advancedcirculatory.com) announced today that it has received an additional $1.5 million in funding from the National Institutes of Health (NIH) to continue a study testing two devices used in combination on those who experience cardiac arrest outside a hospital. Oshkosh is one of six sites included in the national study.

The study is needed because of the dismally low survival rates for cardiac arrest; the national average for surviving such a cardiac arrest that occurs outside a hospital setting is only one in twenty.

The NIH funding will be used to increase enrollment in the six-site study. The study involves the testing of the ResQPump(R) an active compression/decompression device, in combination with the ResQPOD(R), a device used to increase blood flow to the heart and brain during CPR. The ResQPOD, an impedance threshold device proven to increase circulation, has previously received clearance from the FDA and is in use at more than 1,100 customer sites in the US. The current NIH funded study is the first randomized study in the US to assess results of the ResQPump and ResQPOD used together and comparing results when CPR is performed without these devices. The ResQPump has been tested and is currently in use in Europe. Both devices are designed and manufactured by Advanced Circulatory Systems of Minneapolis, MN.

The six sites involved in the study include Minneapolis, MN; St. Paul, MN; Whatcom County, WA; Oshkosh, WI; suburban Detroit including parts of Oakland and Macomb counties, MI; and Livingston County, MI which includes the city of Ann Arbor.

The use of new technologies as well as improved CPR procedures as recommended by the American Heart Association in its latest guidelines are intended to help more people survive a cardiac arrest and with their brain function intact. Studies like the NIH funded study are believed to be among the best methods to prove how treatments can impact outcomes.

Advanced Circulatory Systems' mission is to restore life and improve the quality of life for patients suffering cardiac arrest, low blood pressure and head injury by developing new technologies to non-invasively increase circulation throughout the body, providing improved opportunity for survival and quality of life. The privately held company is based in Minneapolis, MN.

Media contact: Joanne Henry, 612-843-2142, jhenry@henryschafer.com

Advanced Circulatory Systems medical contact: Keith Lurie, M.D., Chief Medical Officer, 952-947-9590, klurie@advancedcirculatory.com

The generally cleared indication for the ResQPOD is a temporary increase in blood circulation during emergency care, hospital, clinic and home use. Studies are ongoing in the United States to evaluate the long-term benefit of the ResQPOD for indications related to patients suffering from cardiac arrest, hypotension during dialysis and severe blood loss. The references in this communication are not intended to imply specific outcome-based claims not yet cleared by the US Food and Drug Administration. Clinical study references are available upon request.


'/>"/>
SOURCE Advanced Circulatory Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology: